抑郁症内源性阿片系统失调及其新治疗方向
本文综述指出内源性阿片系统参与心境调节且在重性抑郁障碍(MDD)中失调,可能解释心境障碍患者阿片类药物处方不成比例的现象。靶向内源性阿片失调的新药有望具有低滥用风险,并产生与传统单胺类抗抑郁药不同的临床获益,或成为应对难治性抑郁的新途径。
要点
- 内源性阿片系统直接参与心境调节,在MDD中失调。
- 心境障碍患者阿片类药物处方不成比例,可能与此失调相关。
- 靶向内源性阿片系统的新药有望低滥用风险且临床获益不同。
核心结论
- 内源性阿片系统失调参与MDD病理生理,靶向该系统的药物可能为MDD尤其是难治性抑郁提供新治疗途径。
- 此类药物相对µ-阿片受体激动剂可能具有低或零滥用与成瘾风险,并可能产生与传统单胺类抗抑郁药性质不同的临床获益。
研究设计与样本
- 本文为综述,汇总内源性阿片系统与MDD及阿片类药物处方相关的研究证据。
主要发现
- 越来越多研究表明内源性阿片系统直接参与心境调节且在MDD中失调。
- 多数阿片类药物处方开给包括MDD在内的心境障碍共病患者。
- 内源性阿片系统参与可能解释心境障碍患者阿片类药物不成比例的使用。
临床怎么用
- 关注MDD患者内源性阿片系统失调,作为难治性抑郁的潜在治疗靶点。
- 开发低滥用风险的内源性阿片系统靶向药物,可能有助于缓解阿片危机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The United States is in the midst of an opioid addiction and overdose crisis precipitated and exacerbated by use of prescription opioid medicines. The majority of opioid prescriptions are dispensed to patients with comorbid mood disorders including major depressive disorder (MDD). A growing body of research indicates that the endogenous opioid system is directly involved in the regulation of mood and is dysregulated in MDD. This involvement of the endogenous opioid system may underlie the disproportionate use of opioids among patients with mood disorders. Emerging approaches to address endogenous opioid dysregulation in MDD may yield novel therapeutics that have a low or absent risk of abuse and addiction relative to µ-opioid agonists. Moreover, agents targeting the endogenous opioid system would be expected to yield clinical benefits qualitatively different from conventional monaminergic antidepressants. The development of safe and effective agents to treat MDD-associated endogenous opioid dysregulation may represent a distinct and currently underappreciated means of addressing treatment resistant depression with the potential to attenuate the on-going opioid crisis.
引用
- Peciña M, Karp JF, Mathew S, et al. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2018. PMID: 29955162. doi:10.1038/s41380-018-0117-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。